scandium has been researched along with Neuroendocrine Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deilami-Nezhad, L; Moghaddam-Banaem, L; Sadeghi, M | 1 |
1 other study(ies) available for scandium and Neuroendocrine Tumors
| Article | Year |
|---|---|
The preparation, biodistribution, and human's absorbed dose evaluation of Radio-Scandium-HYNIC-TOC for somatostatin-receptor-positive neuroendocrine tumors therapy by animal study.
Topics: Animals; Humans; Mice; Neuroendocrine Tumors; Octreotide; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Scandium; Somatostatin; Tissue Distribution | 2022 |